Compare OVLY & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVLY | BNR |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.0M | 233.7M |
| IPO Year | N/A | 2020 |
| Metric | OVLY | BNR |
|---|---|---|
| Price | $27.75 | $16.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.4K | ★ 63.8K |
| Earning Date | 01-23-2026 | 11-20-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $79,783,000.00 | $75,749,382.00 |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.74 | ★ N/A |
| Revenue Growth | 2.98 | ★ 5.56 |
| 52 Week Low | $22.70 | $2.18 |
| 52 Week High | $32.24 | $23.59 |
| Indicator | OVLY | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 48.27 |
| Support Level | $27.66 | $17.66 |
| Resistance Level | $28.25 | $23.59 |
| Average True Range (ATR) | 0.45 | 2.69 |
| MACD | -0.04 | -0.30 |
| Stochastic Oscillator | 68.28 | 17.85 |
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.